GSK GlaxoSmithKline PLC

  • STOCK
  • GSK
  • Price as of: Dec 19, 10:24 PM EST
  • $43.35
  • +$0.06
  • +0.1%
  • Industry
  • Drug manufacturers - major
Share

GSK Stock Dividend Data

Add GSK to Watchlist
  • Dividend Yield
    5.65% Healthcare Average 2.29%
  • Annual Payout
    $2.45 Paid Quarterly
  • Payout Ratio
    80.6% EPS $3.04
  • Dividend Growth
    1 yr Since 2013
  • Get GSK DARS™ Rating
DARS Rating™ Breakdown

Dividend.com DARS Rating™ Breakdown for GSK

Sign Up
Metric GSK Rank GSK Avg Ranking Notes
Relative Strength Sign Up For Ticker Ranking Sign Up For Sector Ranking Stock is performing in-line with the market or better.
Overall Yield Attractiveness Sign Up For Ticker Ranking Sign Up For Sector Ranking Stock's dividend yield is above average.
Dividend Reliability Sign Up For Ticker Ranking Sign Up For Sector Ranking This rating is related to the length and consistency of a company's dividend payouts, as well as our opinion on how likely the company is to continue payouts in the future.
Dividend Uptrend Sign Up For Ticker Ranking Sign Up For Sector Ranking Dividend payouts are consistent, but increases small.
Earnings Growth Sign Up For Ticker Ranking Sign Up For Sector Ranking Earnings estimates are uptrending.
DARS Rating Sign Up For Ticker Ranking Sign Up For Sector Ranking Sign Up For DARS Ratings
Growth History

GSK Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
Reveal More Dividend Growth History for GSK 6.4% 3.9% 1 year
Reveal More Dividend Growth History for GSK
Historical Annual Dividend Data & Growth

GSK Historical Annual Dividend Data & Growth

Payout Amount Calendar Year Annual Growth
$2.4090 2013 3.9%
$2.3194 2012 5.2%
Historical Dividend Data

GSK Dividend History

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$0.6130 2014-11-05 2014-11-07 2015-01-08 Unknown Regular Quarter
$0.6482 2014-08-06 2014-08-08 2014-10-02 Unknown Regular Quarter
$0.6400 2014-05-14 2014-05-16 2014-07-10 Unknown Regular Quarter
$0.7496 2014-02-19 2014-02-21 2014-04-10 Unknown Regular Quarter
$0.6161 2013-11-13 2013-11-15 2014-01-09 Unknown Regular Quarter
$0.5532 2013-08-07 2013-08-09 2013-10-03 Unknown Regular Quarter
$0.5502 2013-05-08 2013-05-10 2013-07-11 Unknown Regular Quarter
$0.6895 2013-02-20 2013-02-22 2013-04-11 Unknown Regular Quarter
$0.5790 2012-11-14 2012-11-16 2013-01-03 Unknown Regular Quarter
$0.5279 2012-08-08 2012-08-10 2012-10-04 Unknown Regular Quarter
$0.5491 2012-05-09 2012-05-11 2012-07-05 Unknown Regular Quarter
$0.6634 2012-02-15 2012-02-17 2012-04-12 Unknown Regular Quarter
$0.1580 2012-02-15 2012-02-17 2012-04-12 Unknown Special N/A
$0.5430 2011-11-02 2011-11-04 2012-01-05 Unknown Regular Quarter
$0.5211 2011-08-03 2011-08-05 2011-10-06 Unknown Regular Quarter
$0.5263 2011-05-04 2011-05-06 2011-07-07 Unknown Regular Quarter
$0.6153 2011-02-09 2011-02-11 2011-04-07 Unknown Regular Quarter
$0.5074 2010-10-27 2010-10-29 2011-01-06 Unknown Regular Quarter
$0.4573 2010-07-28 2010-07-30 2010-10-07 Unknown Regular Quarter
$0.4603 2010-05-05 2010-05-07 2010-07-08 Unknown Regular Quarter
$0.5737 2010-02-10 2010-02-12 2010-04-08 Unknown Regular Quarter
$0.4900 2009-11-04 2009-11-06 2010-01-07 Unknown Regular Quarter
$0.4609 2009-07-29 2009-07-31 2009-10-08 Unknown Regular Quarter
$0.4093 2009-04-29 2009-05-01 2009-07-09 Unknown Regular Quarter
$0.4946 2009-02-11 2009-02-13 2009-04-09 Unknown Regular Quarter
$0.4748 2008-10-29 2008-10-31 2009-01-08 Unknown Regular Quarter
$0.5191 2008-07-30 2008-08-01 2008-10-09 Unknown Regular Quarter
$0.5186 2008-04-30 2008-05-02 2008-07-10 Unknown Regular Quarter
$0.6273 2008-02-13 2008-02-15 2008-04-10 Unknown Regular Quarter
$0.5326 2007-10-31 2007-11-02 2008-01-10 Unknown Regular Quarter
$0.4947 2007-08-01 2007-08-03 2007-10-11 Unknown Regular Quarter
$0.4807 2007-05-02 2007-05-04 2007-07-12 Unknown Regular Quarter
$0.5516 2007-02-14 2007-02-16 2007-04-12 Unknown Regular Quarter
$0.4505 2006-11-01 2006-11-03 2007-01-04 Unknown Regular Quarter
$0.4063 2006-08-02 2006-08-04 2006-10-05 Unknown Regular Quarter
$0.3932 2006-05-10 2006-05-12 2006-07-06 Unknown Regular Quarter
$0.4875 2006-02-15 2006-02-17 2006-04-06 Unknown Regular Quarter
$0.3552 2005-11-02 2005-11-04 2006-01-05 Unknown Regular Quarter
$0.3478 2005-08-03 2005-08-05 2005-10-06 Unknown Regular Quarter
$0.3801 2005-05-11 2005-05-13 2005-07-07 Unknown Regular Quarter
$0.4444 2005-02-16 2005-02-18 2005-04-07 Unknown Regular Quarter
$0.3652 2004-11-03 2004-11-05 2005-01-06 Unknown Regular Quarter
$0.3659 2004-08-04 2004-08-06 2004-09-30 Unknown Regular Quarter
$0.3528 2004-05-12 2004-05-14 2004-07-01 Unknown Regular Quarter
$0.5199 2004-02-18 2004-02-20 2004-04-15 Unknown Regular Quarter
$0.3002 2003-10-29 2003-10-31 2004-01-06 Unknown Regular Quarter
$0.2864 2003-07-30 2003-08-01 2003-10-02 Yes Regular Quarter
$0.2851 2003-05-07 2003-05-09 2003-07-03 Yes Regular Quarter
$0.4187 2003-02-19 2003-02-21 2003-04-17 Yes Regular Quarter
$0.2772 2002-10-30 2002-11-01 2003-01-03 Yes Regular Quarter
$0.2803 2002-07-31 2002-08-02 2002-10-03 Unknown Regular Quarter
$0.2596 2002-05-01 2002-05-03 2002-07-05 Unknown Regular Quarter
$0.3423 2002-02-20 2002-02-22 2002-04-18 Unknown Regular Quarter
$0.2558 2001-10-31 2001-11-02 2002-01-03 Unknown Regular Quarter
$0.2546 2001-08-01 2001-08-03 2001-10-04 Unknown Unknown unknown
$0.2586 2001-05-02 2001-05-04 2001-07-05 Unknown Unknown unknown
Company Profile

GSK Company Profile

Exchange: NYSE
Sector: Healthcare

GlaxoSmithKline (GSK) is a global healthcare group. The company focuses on the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK was founded in 1999, and is based in the UK. In April 2014, GSK sold its cancer-drug business to Novartis for $14.5 billion and acquired Novartis’s vaccines business for $7.1 billion, along with creating a new consumer health business by operating a joint venture. GSK operates in a highly competitive business, and relies on patent protection and market exclusivity for its products to achieve high levels of profitability. GSK’s success is also dependent on its ability to continuously develop new pharmaceutical products. GSK has been paying a dividend since 2001 and has been increasing it consistently since 2009, which is when it last cut its payout. GSK pays its dividends quarterly.

High Yield Stocks

High Yield Stocks

Looking for dividend stocks with great yields? Visit our list of:

High Yield Dividend Stocks
News

GlaxoSmithKline PLC News

  • Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
  • Here at Dividend.com, we constantly emphasize the importance of strong fundamentals when it comes to making any investment decision. However, with...
  • Following news that UK-based GlaxoSmithKline plc (GSK) bribed doctors and officials to improve sales in China, the drugmaker announced that it...
  • GlaxoSmithKline to Sell Thrombosis Brands for $1.13B (GSK)

    GlaxoSmithKline plc (GSK) announced on Monday that it has agreed to sell its thrombosis drugs, Arixtra and Fraxiparine, and its Notre-Dame de Bondeville manufacturing facility for $1.13 billion. The British pharmaceutical company will sell both drug brands along with its manufacturing facility to The Aspen Group for £700 million or $1.13 billion in cash. This sale will allow GSK to focus on products with higher growth potential. GSK Chief Strategy Officer David Redfern commented: "Arixtra and Fraxiparine are established products that have consistently delivered strong revenues. However, our focus is on delivering an unprecedented late-stage pipeline and preparing for the launch of approved medicines. Aspen is a long-term partner of GSK and will be able to dedicate the resources that these products deserve to take them forward." GlaxoSmithKline shares were mostly flat during pre-market trading Monday. The stock is up 16% YTD.

    The Bottom Line

    Shares of GlaxoSmithKline plc (GSK) have a 4.38% yield based on Friday's closing price of $50.48. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • GlaxoSmithKline Upgraded to "Neutral" at JP Morgan (GSK)

    JP Morgan reported on Wednesday that it has upgraded healthcare company GlaxoSmithKline plc (GSK) . The firm has raised its rating on GSK to "Neutral" as analysts see upcoming catalysts balancing out risk. GlaxoSmithKline shares were up 29 cents, or 0.56%, during pre-market trading Wednesday. The stock is up 20% YTD. The Bottom Line Shares of GlaxoSmithKline plc (GSK) have a 4.25% yield based on Tuesday's closing price of $52.01. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • JP Morgan Gets Bearish on GlaxoSmithKline; Says 2013 Earnings are at Risk (GSK)

    U.K.-based pharmaceutical giant GlaxoSmithKline plc (GSK) on Wednesday caught a big downgrade from analysts at JP Morgan. The firm slashed its rating on GSK from "Neutral" to "Underweight," noting worries about the company's upcoming earnings. A JP Morgan analyst commented, "With material risk to 2013 earnings, no imminent positive catalysts, and almost no upside to our new PT, we downgrade to Underweight. GSK is entering an investment phase. After reassessing the investment required to execute on the pipeline, already taken for granted by consensus, we now expect Operating margins to contract, rather than expand in 2013, and we now forecast a 2013 Operating margin 200bps below consensus. We see earnings risk in 2013, with material Operating profit and earnings growth unlikely for at least a year further out than is currently forecast by consensus (which expects topline growth and margin expansion in 2013)." GlaxoSmithKline shares fell 53 cents, or -1.2%, in premarket trading Wednesday. The Bottom Line Shares of GlaxoSmithKline plc (GSK) have a 4.78% dividend yield, based on last night's closing stock price of $46.07. The stock has technical support in the $43-$44 price area. If the shares can firm up, we see overhead resistance around the $48-$50 price levels. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Acuity Brands...
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Deutsche Bank...
  • FDA Approves GlaxoSmithKline's Lupus Treatment (GSK)

    British pharmaceutical giant GlaxoSmithKline plc (GSK) got some welcome news from the FDA late Wednesday night, as the federal regulator approved a lupus treatment drug that GSK has been pegged to market. The drug, called Benlysta, was developed by U.S.-based Human Genome Sciences (HGSI) and will be marketed and sold by GSK. Benlysta is the first lupus treatment drug approved in the U.S. since 1955. Lupus, a potentially fatal autoimmune disease, affects 1.5 million Americans and 5 million people worldwide, according to the Lupus Foundation of America. GlaxoSmithKline shares rose 20 cents, or +0.5%, in premarket trading Thursday. The Bottom Line Shares of GlaxoSmithKline (GSK) have a 6.38% dividend yield, based on last night's closing stock price of $38.58. The stock has technical support in the $36 price area. If the shares can firm up, we see overhead resistance around the $40-$42 price levels. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Beckman Coulter...